Pacira | PCRX - Interest Expense On Debt


Pacira reported $4.28M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Astellas Pharma JPY 3.91B 320M Mar/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 18M 290M Sep/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Xeris Pharmaceuticals USD 7.27M 92K Sep/2025
Zoetis USD 58M 5M Sep/2025